Poplar Therapeutics vs ImmunoVec
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $95M total ($50M Series A Jan 2026 + $45M extension Mar 2026) from SR One, Vida, RA Capital, Janus Henderson. Triple-action anti-IgE mechanism. Phase 1 data expected H2 2026 for PHB-050.
About
Poplar Therapeutics (formerly Phylaxis Bioscience) raised $95 million in less than 60 days — $50 million in Series A financing in January 2026 from SR One, Vida Ventures, RA Capital, and Janus Henderson, extended by $45 million in March 2026 — reflecting exceptional investor conviction in its PHB-050 anti-IgE program. PHB-050 uses a triple-action anti-IgE mechanism designed to exceed the performance of existing anti-IgE drugs: simultaneously blocking mast cell IgE binding, reducing circulating free IgE, and inhibiting IgE production by B cells. Phase 1 data is expected in the second half of 2026.
Received up to $40.7M ARPA-H award (Oct 2025). Polymeric nanoparticle platform to reprogram immune cells in vivo without viral vectors. Non-viral delivery for CAR-T-like therapies.
About
ImmunoVec is developing a non-viral polymeric nanoparticle delivery platform for in vivo immune cell engineering — programming a patient's immune cells directly inside their body without the expensive ex vivo manufacturing process that makes CAR-T therapies cost $500,000-$1,000,000 per treatment. The company received a selective ARPA-H (Advanced Research Projects Agency for Health) award of up to $40.7 million in October 2025 for development of its platform.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.